- Contract manufacturer Catalent announced Tuesday it will buy Pharmatek Laboratories, a West Coast-based drug development and clinical manufacturing specialist.
- The acquisition will add to Catalent's drug development services and dry spraying technology.
- Pharmatek's facility in San Diego has about 200 employees "whose experience and expertise will complement Catalent’s existing development and analytical services teams," said the buyer.
Catalent is picking up Pharmatek's cGMP facility with 68,000 square feet of laboratory, manufacturing and support space, as well as two analytical labs, two formulation labs, four engineering rooms and nine Certified ISO Class 8 manufacturing suites.
The facility in San Diego also has 18,000 square feet of laboratory, manufacturing and support space dedicated specifically to development and manufacturing of highly-potent compounds.
"Combined with Catalent’s existing technologies and network, the addition of Pharmatek’s well-established scientific expertise and spray dry capabilities will create an unparalleled drug development platform, while the San Diego facility will expand our West Coast presence and provides additional access to the Asia-Pacific markets," said Barry Littlejohns, president of Catalent’s drug delivery solutions business.
The company has made several acquisitions since entering the public market in 2014, including its buyout of Pharmapak and Micron Technologies.